Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:29PM EST. Market open.
| Previous close | 229.75 |
| Open | 228.38 |
| Bid | 231.91 x 1000 |
| Ask | 232.33 x 1300 |
| Day's range | 227.62 - 233.76 |
| 52-week range | 117.58 - 242.97 |
| Volume | |
| Avg. volume | 749,683 |
| Market cap | 28.72B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.49 |
| Earnings date | 23 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 246.39 |
- Zacks
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass., February 02, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.
- Zacks
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
© 2023 Yahoo. All rights reserved.
